Deloitte Legal assists Rejuvenate Biomed NV in raising 15.7 million eur in its Series B financing route

Taking on your challenges

13 October 2021

Rejuvenate Biomed NV is a Belgian based biomedical company developing novel combination drugs that delay or prevent the onset of multiple age-related diseases, with a focus on the intersection between fundamental aging mechanisms and chronic conditions.

Deloitte Legal is proud to have assisted Rejuvenate Biomed NV regarding
the raise of a EUR 15.7 million Series B financing round to accelerate the
clinical development of Rejuvenate’s lead drug candidate RJx-01 in sarcopenia
treatment for healthy aging. The funds will also go towards exploring the
treatment’s potential in other diseases, as well as further developing the
company’s in silico screening platform and pipeline of other
drug candidates. 

The Deloitte Legal Corporate and M&A team was led by Christoph Michiels and comprised team members Sander Kevelaerts and Elena Vromans.

Read the Rejuvenate Biomed press release.

Did you find this useful?